Literature DB >> 10725252

Enhanced blood pressure sensitivity to DOCA-salt treatment in endothelin ET(B) receptor-deficient rats.

Y Matsumura1, T Kuro, F Konishi, M Takaoka, C E Gariepy, M Yanagisawa.   

Abstract

The role of endothelin ET(B) receptor-mediated action in the development and maintenance of deoxycorticosterone acetate (DOCA)-salt-induced hypertension was evaluated using the spotting-lethal (sl) rat which carries a naturally occurring deletion in the ET(B) receptor gene. Homozygous (sl/sl) rats treated with DOCA-salt for 1 week exhibited an earlier onset of hypertension than heterozygous (sl/+) and wild-type (+/+) rats (systolic blood pressure, SBP; 156.7+/-3.4 versus 128.8+/-5.3 and 132.9+/-3.7 mmHg, respectively). Four weeks after the start of DOCA-salt treatment, homozygous rats developed marked hypertension, with a SBP of 206. 0+/-4.5 mmHg, compared with 184.8+/-10.7 mmHg in heterozygous and 164.3+/-4.8 mmHg in wild-type rats. Cardiovascular hypertrophy and renal dysfunction observed after 4-weeks treatment with DOCA-salt were more severe in homozygous rats, compared to wild-type and heterozygous animals. These evidences support strongly the view that ET(B) receptor-mediated actions are a protective factor in the pathogenesis of DOCA-salt-induced hypertension.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725252      PMCID: PMC1571939          DOI: 10.1038/sj.bjp.0703157

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

1.  Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats.

Authors:  E L Schiffrin; A Turgeon; L Y Deng
Journal:  Br J Pharmacol       Date:  1997-07       Impact factor: 8.739

Review 2.  Molecular pharmacology and pathophysiological significance of endothelin.

Authors:  K Goto; H Hama; Y Kasuya
Journal:  Jpn J Pharmacol       Date:  1996-12

3.  Transgenic expression of the endothelin-B receptor prevents congenital intestinal aganglionosis in a rat model of Hirschsprung disease.

Authors:  C E Gariepy; S C Williams; J A Richardson; R E Hammer; M Yanagisawa
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

4.  Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats.

Authors:  Y Matsumura; N Hashimoto; S Taira; T Kuro; R Kitano; M Ohkita; T J Opgenorth; M Takaoka
Journal:  Hypertension       Date:  1999-02       Impact factor: 10.190

5.  Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats.

Authors:  R Larivière; G Thibault; E L Schiffrin
Journal:  Hypertension       Date:  1993-03       Impact factor: 10.190

Review 6.  Endothelin: potential role in hypertension and vascular hypertrophy.

Authors:  E L Schiffrin
Journal:  Hypertension       Date:  1995-06       Impact factor: 10.190

7.  Antihypertensive effects of a novel endothelin-A receptor antagonist in rats.

Authors:  J E Bird; S Moreland; T L Waldron; J R Powell
Journal:  Hypertension       Date:  1995-06       Impact factor: 10.190

8.  Endothelin ET(B) receptor-mediated action on systemic and renal hemodynamics and urine formation in deoxycorticosterone acetate-salt-induced hypertensive rats.

Authors:  N Hashimoto; T Kuro; K Fujita; S Azuma; Y Matsumura
Journal:  Biol Pharm Bull       Date:  1998-08       Impact factor: 2.233

9.  Pharmacologic characterization of an endothelinA (ETA) receptor antagonist in conscious rats.

Authors:  M K Bazil; R W Lappe; R L Webb
Journal:  J Cardiovasc Pharmacol       Date:  1992-12       Impact factor: 3.105

10.  Role of endothelin-1 and the ETA receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension.

Authors:  K Fujita; Y Matsumura; S Kita; Y Miyazaki; K Hisaki; M Takaoka; S Morimoto
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

View more
  9 in total

1.  Role of endothelin and vasopressin in DOCA-salt hypertension.

Authors:  M Yu; V Gopalakrishnan; J R McNeill
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

2.  Regulation of the epithelial Na+ channel by endothelin-1 in rat collecting duct.

Authors:  Vladislav Bugaj; Oleh Pochynyuk; Elena Mironova; Alain Vandewalle; Jorge L Medina; James D Stockand
Journal:  Am J Physiol Renal Physiol       Date:  2008-07-30

3.  Aldosterone modulates steroid receptor binding to the endothelin-1 gene (edn1).

Authors:  Lisa R Stow; Michelle L Gumz; I Jeanette Lynch; Megan M Greenlee; Alicia Rudin; Brian D Cain; Charles S Wingo
Journal:  J Biol Chem       Date:  2009-07-28       Impact factor: 5.157

4.  Bioconversion of Corticosterone into Corticosterone-Glucoside by Glucosyltransferase.

Authors:  Tokutaro Yamaguchi; Joo-Ho Lee; A-Rang Lim; Joon-Soo Sim; Eun-Ji Yu; Tae-Jin Oh
Journal:  Molecules       Date:  2018-07-19       Impact factor: 4.411

Review 5.  Heart failure with preserved ejection fraction: present status and future directions.

Authors:  Somy Yoon; Gwang Hyeon Eom
Journal:  Exp Mol Med       Date:  2019-12-19       Impact factor: 8.718

Review 6.  Application of Animal Models in Diabetic Cardiomyopathy.

Authors:  Wang-Soo Lee; Jaetaek Kim
Journal:  Diabetes Metab J       Date:  2021-03-25       Impact factor: 5.376

Review 7.  Age and Sex Differences in Heart Failure With Preserved Ejection Fraction.

Authors:  Kamil Aleksander Kobak; Weronika Zarzycka; Ying Ann Chiao
Journal:  Front Aging       Date:  2022-02-15

Review 8.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

9.  Murine Models of Heart Failure with Preserved Ejection Fraction: a "Fishing Expedition".

Authors:  Maria Valero-Muñoz; Warren Backman; Flora Sam
Journal:  JACC Basic Transl Sci       Date:  2017-12-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.